

Tuesday, March 1st 2005

FOR IMMEDIATE RELEASE

OBJ DEMONSTRATES FINE CONTROL OVER DRUG DELIVERY RATES

=====

OBJ Limited (OBJ) is pleased to announce that its Dermaportation drug delivery technology had successfully demonstrated the ability to provide a high level of control over drug delivery rates in vitro .

In an independent research program, conducted the Western Australia Biomedical Research Institute (WABRI), found that Dermaportation was able to control the delivery rates of the drug caffeine through donated human skin, across a range of delivery rates from t 0.6 µg/cm² through to 19.2 µg/cm².

The research program, which sought to define Dermaportation's high resolution control processes, showed that fine management control could be achieved using OBJ's electronic patch technology.

WABRI found that Dermaportation could either accelerate rates of drug delivery by as much as 280% or decrease them to 36%.

The new findings will be presented at the annual conference of the Australian Society of Cosmetic Chemists Brisbane on March 17th-20th.

The company believes that these promising results represent a significant step forward in drug delivery technology.

END:

Background to the Announcement

OBJ Limited is a drug delivery company, developing electronic “drug patch” technologies that allow drugs, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently through-the-skin.

OBJ’s technology works by temporarily changing the skin’s barrier effect. As this does not involve a change to the target drug or compound, new and effective delivery strategies can be created without the necessity for the drug to undergo costly re-registration. This technology provides pharmaceutical companies with a market friendly, cost effective and safe route of administration for many existing and newly created drugs and compounds.

The company has previously announced a 600% increase in the rate of delivery of the drug caffeine and a 70% reduction in the through-the-skin delivery times for the anaesthetic drugs lignocaine and prilocaine hydrochloride.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute or WABRI and Universities.

WABRI is a government owned and funded drug development and testing facility operated by Curtin University. The high level of independence and international accreditation means that the results by OBJ can be published and presented at major medical and scientific conferences and forums.

For more information:

Jeffrey Edwards
Phone: +61 8 944 33011
Mobile: 041 791 2211
E-mail: jedwards@obj.com.au